Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Considering MNTA and NVS were vocal about having a stockpile of product ready upon approval (and CW's over-bullishness) who can blame them for thinking such?
any other explanations? Perhaps MNTA is close? :)
Another TEVA CP. http://www.regulations.gov/#!documentDetail;D=FDA-2012-P-0555-0001
If it's already been posted apologies and feel free to delete
nice copax comments... CW seems the most bullish he's ever been on it. I like that he stated he feels like he did during the enox approval process.
someone picked up over 5k July 19 calls today :)
too many unknowns for ole MNTA right now... Wouldn't be surprised to see 12s or even lower....
Speaking of FWIW, picked up some shares today in the 13.70s.
Hi Jbog :)
MNTA holding that 14 line in a very bloody market...OPEX games?
What would the significance of TEVA's involvement be here?
Hard to say especially if they lose the copax patents...but right now MNTA is worth about $300m after cash... Pretty cheap...one would think
I miss Beverly. The new IR person isn't half as good as she was (and she barely responds).
Anything else of note on the call about the CAFC ruling, m-copax, etc?
Another hint that these are new is MNTA's expenses going up this year.
I would imagine because the news is meaningless unless WPI/Ampha are in face forced to withdraw their product...
Isn't Wedbush also in the MNTA will prevail camp?
Merrill Lynch sees Teva win in Copaxone patent cases
Merrill Lynch predicts that generic Copaxone will not enter the market until mid-2015, rather than in 2013.
6 March 12 12:47
Merrill Lynch predicts that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) will win its patent case to protect Copaxone, its intravenous treatment for multiple sclerosis, and therefore reiterated its "Buy" recommendation raised its target price to $57 from $55.
Merrill Lynch analysts Gregg Gilbert, Haim Israel, and Sumant Kulkarni also predict that generic Copaxone will enter the market in mid-2015, rather than in 2013, which they say was an overly conservative estimate.
US district court rulings on the two patent challenges to Copaxone by Momenta Pharmaceuticals Inc. (Nasdaq: MNTA) and Sandoz Inc. and by Mylan Inc. (NYSE: MYL) and India's Natco Pharma Ltd. could come at any time. Copaxone is protected by seven Orange Book-listed patents (all expire on May 24, 2014), which are part of litigation. The analysts estimate that Copaxone will have $2.6 billion in US sales in 2012.
In separate developments, several generic companies are challenging Teva's Nuvigil for excessive daytime sleepiness, with trials against Mylan and Watson Pharmaceuticals Inc. (NYSE: WPI) scheduled for June. The analysts expect a settlement to allow generics to enter the market on January 1, 2015, instead of in 2018.
Merrill Lynch forecasts Teva's earnings per share of $5.58 on $21.65 billion revenue in 2012 and $6.21 on $22.22 billion revenue in 2013.
UBS also reiterates its "Buy" recommendation for Teva with a target price of $60. It cited yesterday's announcement of positive results in a Phase III clinical trial of QNASL for the treatment of seasonal and perennial allergic rhinitis
Teva's share price fell 0.6% by early afternoon on the TASE today to NIS 171.20, after falling 0.4% on Nasdaq yesterday to $45.06, giving a market cap of $42.5 billion.
Qnexa and M-copax are apples and oranges in pretty much every regard... not sure where you're making a connection?
And the March calls keep stacking up.....
MNTA 13Gs coming out... Looks like Scopia Management now has 4.6m shares?
Exelixis Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (Nasdaq:EXEL - News) today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares in the offering will be sold by Exelixis. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3.
Goldman, Sachs & Co. is acting as sole book running manager, and Cowen and Company, LLC is acting as co-manager of the offering.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Goldman, Sachs & Co. (200 West Street, New York, New York 10282, Attn: Prospectus Department, Phone: 1-866-471-2526, Fax: 212-902-9316, Email: prospectus-ny@ny.email.gs.com) or from Cowen and Company, LLC (c/o Broadridge Financial Services., 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). Exelixis intends to file a preliminary prospectus supplement relating to the offering with the SEC, which will be available along with the prospectus filed with the SEC in connection with the shelf registration, on the SEC’s website at http://www.sec.gov/.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements relating to Exelixis’s expectations regarding the completion, timing and size of the proposed public offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and Exelixis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Exelixis will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Exelixis and its business can be found in the “Risk Factors” section of Exelixis’s Form 10-Q, filed with the SEC on October 27, 2011, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC. Exelixis undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Exelixis’s expectations.
Thanks for response... makes sense
So just to be clear, if MNTA/NVS end up winning, is Ampha then required to pull their drug in addition to payments?
there will be an "update" about enox Thursday during the call... what that update is, who knows!
still silence.... :)
A lot can happen from now until the 9th....
WPI was just as shocked as us...
Very true. In fact, MNTA wanted the enox contract renegotiated but to MNTA's chagrin, Sandoz wouldn't have it.
Also pretty significant volume on those march puts, as well
$225m 4th q enox sales
AT WPI analyst event today, they stated they aren't including a-enox for 2012 guidance..
WPI: At an analyst event today they said they aren't including generic lovenox for 2012 guidance
I just listened, and I admit it's a bit over my head, but I must I am a bit nervous... Is is it normal in these kinds of things for the judges to grill the plaintiffs like this? It seems like they weren't buying MNTA/Sandoz's argument that you can get approval without MNTA's test (so long as it is the same or better)...
Although i like this from the judge to Ampha's lawyers "If it was up to you, would all manufacturing patents be worthless?"
I'm talking about what the perceived chances were of MNTA/Sandoz winning the lovenox patent case with SNY before it was decided, if that makes sense??
oops! Don't think I was clear with my original question! :)
When I said lovenox patent trial, I actually meant the lovenox patent trial with SNY rather than the one with Ampha!
Anyone recall what the consensus was of MNTA's chances to win the lovenox patent trial? Was it similar to M-copax, or was there more certainty regarding MNTA's chances of victory?? Not all that important, but just trying to get some perspective. TIA